MWMi Wu

Mi Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mi Wu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functional Heterogeneity of Hepatitis B Virus-Specific CD8+ T Cells Mediates the Clinical Outcomes of Infection

    by Zhijun Shen, Xin Wang, Juan Zhao, Mi Wu, Ting Zhou, Lichen Ouyang, Xiufang Weng, Shiguo Liu, Xiongwen Wu

    Background: Hepatitis B virus (HBV)-specific CD8+ T cells play a crucial role in viral clearance. However, in patients with chronic hepatitis B infections, sustained immune activation leads to functional impairment of these HBV-specific CD8+ T cells. The goal of this study was to clarify whether these virus-specific CD8+ T cells are exhausted or reflect an incomplete response derived from the initial T cell repertoire. Methods: In this study, HBV core 18–27 epitope-specific CD8+ T cells were identified by proliferation through in vitro antigen stimulation. Peptide-specific CD8+ T cells recognizing the cytomegalovirus (CMV) pp65 495–503 epitope were used as a positive control, as they exhibit a robust immune response. Single-cell sequencing was employed to characterize the TCR repertoire of expanded clones. Correlations between T cell subsets and clinical outcomes were analyzed and compared. Results: Both HBV core 18–27-specific and CMV pp65-specific CD8+ T cells were successfully classified into three functionally distinct subsets: IFNγ+, mTGFβ+, and IFNγ–/mTGFβ–. Those patients with resolved acute HBV infections and HBV core 18–27 specific CD8+ T cells exhibited the highest IFNγ+/mTGFβ+ ratio, reaching levels comparable to those of CMV pp65-specific CD8+ T cells. Inactive HBV carriers exhibited the second-highest IFNγ+/mTGFβ+ ratio, while this ratio was lowest among patients exhibiting viral immune tolerance. HBV core 18–27 tetramer staining and ERGO-Ⅱ Model prediction demonstrated that IFNγ+ subset CD8+ T cells exhibited the highest affinity for this epitope, followed by the mTGFβ+ subset, with IFNγ–/mTGFβ– cells exhibiting the lowest affinity. Conclusions: These results suggest that individuals with a high IFNγ+/mTGFβ+ ratio exhibit a lower HBV viral load. The IFNγ+/mTGFβ+ CD8+ T cell ratio, in particular, appears to be associated with HBV clearance, and this may be attributable to T cell receptor affinity for HBV epitopes.

  • Open Access

    Supplementary Data from Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma

    by Xue Cheng, Xiaosheng Tan, Wei Wang, Ziyao Zhang, Rongfei Zhu, Mi Wu, Mingyu Li, Yiqing Chen, Zhihui Liang, Peng Zhu, et al.

    Supplementary figures and figure legends

  • Open Access

    Data from Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma

    by Xue Cheng, Xiaosheng Tan, Wei Wang, Ziyao Zhang, Rongfei Zhu, Mi Wu, Mingyu Li, Yiqing Chen, Zhihui Liang, Peng Zhu, et al.

    CD1d-restricted invariant natural killer T (iNKT) cells actively patrol the liver and possess valuable antitumor potential. However, clinical trials evaluating administration of iNKT cell–specific agonist α-galactosylceramide (α-GalCer) have failed to achieve obvious tumor regression. Improving the efficacy of iNKT cell–based immunotherapy requires a better understanding of the factors restraining the clinical benefits. In the context of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we found circulating and hepatic iNKT cells were hyperactivated but demonstrated imbalances in ratio and defective α-GalCer responsiveness. Exogenous IL2 helped to expand residual α-GalCer–responsive clones with reduced T-cell receptor diversity. However, transcriptome-wide analysis revealed activation of the senescence-associated secretory phenotype and dampened cytotoxicity in iNKT cells, weakening their immune surveillance capacity. The senescent status of iNKT cells from the patients was further illustrated by cell-cycle arrest, impaired telomere maintenance, perturbed calcium transport-related biological processes, and altered metabolism. Lipidomic profiling revealed the accumulation of long-chain acylcarnitines (LCAC) and aberrant lipid metabolism in HCC tissue. Exogenous LCACs, especially palmitoyl-carnitine and stearoyl-carnitine, inhibited iNKT cell expansion and promoted senescence. Collectively, our results provide deeper insights into iNKT cell dysregulation and identify a cell senescence–associated challenge for iNKT cell–based immunotherapy in HBV-related HCC. The mechanistic links between iNKT cell senescence and accumulated LCACs suggest new targets for anti-HCC immunotherapies.Significance:Patients with HBV-related HCC exhibit a cell senescence–associated dysregulation of invariant natural killer cells that is related to altered lipid metabolism and accumulated LCACs in tumor tissue.

  • Open Access

    Supplementary Data from Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma

    by Xue Cheng, Xiaosheng Tan, Wei Wang, Ziyao Zhang, Rongfei Zhu, Mi Wu, Mingyu Li, Yiqing Chen, Zhihui Liang, Peng Zhu, et al.

    Supplementary figures and figure legends

  • Open Access

    Data from Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma

    by Xue Cheng, Xiaosheng Tan, Wei Wang, Ziyao Zhang, Rongfei Zhu, Mi Wu, Mingyu Li, Yiqing Chen, Zhihui Liang, Peng Zhu, et al.

    CD1d-restricted invariant natural killer T (iNKT) cells actively patrol the liver and possess valuable antitumor potential. However, clinical trials evaluating administration of iNKT cell–specific agonist α-galactosylceramide (α-GalCer) have failed to achieve obvious tumor regression. Improving the efficacy of iNKT cell–based immunotherapy requires a better understanding of the factors restraining the clinical benefits. In the context of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we found circulating and hepatic iNKT cells were hyperactivated but demonstrated imbalances in ratio and defective α-GalCer responsiveness. Exogenous IL2 helped to expand residual α-GalCer–responsive clones with reduced T-cell receptor diversity. However, transcriptome-wide analysis revealed activation of the senescence-associated secretory phenotype and dampened cytotoxicity in iNKT cells, weakening their immune surveillance capacity. The senescent status of iNKT cells from the patients was further illustrated by cell-cycle arrest, impaired telomere maintenance, perturbed calcium transport-related biological processes, and altered metabolism. Lipidomic profiling revealed the accumulation of long-chain acylcarnitines (LCAC) and aberrant lipid metabolism in HCC tissue. Exogenous LCACs, especially palmitoyl-carnitine and stearoyl-carnitine, inhibited iNKT cell expansion and promoted senescence. Collectively, our results provide deeper insights into iNKT cell dysregulation and identify a cell senescence–associated challenge for iNKT cell–based immunotherapy in HBV-related HCC. The mechanistic links between iNKT cell senescence and accumulated LCACs suggest new targets for anti-HCC immunotherapies.Significance:Patients with HBV-related HCC exhibit a cell senescence–associated dysregulation of invariant natural killer cells that is related to altered lipid metabolism and accumulated LCACs in tumor tissue.

  • Open Access

    Supplementary Data from Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma

    by Xue Cheng, Xiaosheng Tan, Wei Wang, Ziyao Zhang, Rongfei Zhu, Mi Wu, Mingyu Li, Yiqing Chen, Zhihui Liang, Peng Zhu, et al.

    Supplementary figures and figure legends

  • Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma

    by Xue Cheng, Xiaosheng Tan, Wei Wang, Ziyao Zhang, Rongfei Zhu, Mi Wu, Mingyu Li, Yiqing Chen, Zhihui Liang, Peng Zhu, et al.

    CD1d-restricted invariant natural killer T (iNKT) cells actively patrol the liver and possess valuable antitumor potential. However, clinical trials evaluating administration of iNKT cell–specific agonist α-galactosylceramide (α-GalCer) have failed to achieve obvious tumor regression. Improving the efficacy of iNKT cell–based immunotherapy requires a better understanding of the factors restraining the clinical benefits. In the context of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we found circulating and hepatic iNKT cells were hyperactivated but demonstrated imbalances in ratio and defective α-GalCer responsiveness. Exogenous IL2 helped to expand residual α-GalCer–responsive clones with reduced T-cell receptor diversity. However, transcriptome-wide analysis revealed activation of the senescence-associated secretory phenotype and dampened cytotoxicity in iNKT cells, weakening their immune surveillance capacity. The senescent status of iNKT cells from the patients was further illustrated by cell-cycle arrest, impaired telomere maintenance, perturbed calcium transport-related biological processes, and altered metabolism. Lipidomic profiling revealed the accumulation of long-chain acylcarnitines (LCAC) and aberrant lipid metabolism in HCC tissue. Exogenous LCACs, especially palmitoyl-carnitine and stearoyl-carnitine, inhibited iNKT cell expansion and promoted senescence. Collectively, our results provide deeper insights into iNKT cell dysregulation and identify a cell senescence–associated challenge for iNKT cell–based immunotherapy in HBV-related HCC. The mechanistic links between iNKT cell senescence and accumulated LCACs suggest new targets for anti-HCC immunotherapies. Significance: Patients with HBV-related HCC exhibit a cell senescence–associated dysregulation of invariant natural killer cells that is related to altered lipid metabolism and accumulated LCACs in tumor tissue.